Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity

Adam Gibb; Sarah Pirrie; Kim Linton; Kathryn Paterson; Andrew Davies; Graham P. Collins; Tobias Menne; Pamela McKay; Paul Fields; Fiona Miall; Eszter  Nagy; Keith  Wheatley; Keith  Wheatley; Sally Barrington; John Radford

Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity

Adam Gibb, Sarah Pirrie, Kim Linton, Kathryn Paterson, Andrew Davies, Graham P. Collins, Tobias Menne, Pamela McKay, Paul Fields, Fiona Miall, Eszter Nagy, Keith Wheatley, Keith Wheatley, Sally Barrington, John Radford

Division of Cancer Sciences (L5)

Research output: Chapter in Book/Conference proceeding › Conference contribution › peer-review

Original language	English
Title of host publication	. Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity
Publisher	Ferrata Storti Foundation
Publication status	Published - 2016
Event	10th International Symposium for Hodgkin Lymphoma (ISHL) - Cologne, Germany Duration: 22 Oct 2016 → 25 Oct 2016 Conference number: 10

Conference

Conference	10th International Symposium for Hodgkin Lymphoma (ISHL)
Abbreviated title	ISHL
Country/Territory	Germany
City	Cologne
Period	22/10/16 → 25/10/16

Keywords

Hodgkin lymphoma
Brentuximab vedotin
Antibody drug conjugate
Elderly
Frail

Research Beacons, Institutes and Platforms

Cancer
Manchester Cancer Research Centre

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Cite this

Gibb, A., Pirrie, S., Linton, K., Paterson, K., Davies, A., Collins, G. P., Menne, T., McKay, P., Fields, P., Miall, F., Nagy, E., Wheatley, K., Wheatley, K., Barrington, S., & Radford, J. (2016). Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity. In . Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity Ferrata Storti Foundation.

Gibb, Adam ; Pirrie, Sarah ; Linton, Kim et al. / Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity. . Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity. Ferrata Storti Foundation, 2016.

@inproceedings{6a91a188d5234d258f5c92171cce82c5,

title = "Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity",

keywords = "Hodgkin lymphoma, Brentuximab vedotin, Antibody drug conjugate, Elderly, Frail",

author = "Adam Gibb and Sarah Pirrie and Kim Linton and Kathryn Paterson and Andrew Davies and Collins, {Graham P.} and Tobias Menne and Pamela McKay and Paul Fields and Fiona Miall and Eszter Nagy and Keith Wheatley and Keith Wheatley and Sally Barrington and John Radford",

year = "2016",

language = "English",

booktitle = ". Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity",

publisher = "Ferrata Storti Foundation",

address = "Italy",

note = "10th International Symposium for Hodgkin Lymphoma (ISHL), ISHL ; Conference date: 22-10-2016 Through 25-10-2016",

}

Gibb, A, Pirrie, S, Linton, K, Paterson, K, Davies, A, Collins, GP, Menne, T, McKay, P, Fields, P, Miall, F, Nagy, E, Wheatley, K, Wheatley, K, Barrington, S & Radford, J 2016, Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity. in . Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity. Ferrata Storti Foundation, 10th International Symposium for Hodgkin Lymphoma (ISHL), Cologne, Germany, 22/10/16.

Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity. / Gibb, Adam; Pirrie, Sarah; Linton, Kim et al.
. Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity. Ferrata Storti Foundation, 2016.

Research output: Chapter in Book/Conference proceeding › Conference contribution › peer-review

TY - GEN

T1 - Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity

AU - Gibb, Adam

AU - Pirrie, Sarah

AU - Linton, Kim

AU - Paterson, Kathryn

AU - Davies, Andrew

AU - Collins, Graham P.

AU - Menne, Tobias

AU - McKay, Pamela

AU - Fields, Paul

AU - Miall, Fiona

AU - Nagy, Eszter

AU - Wheatley, Keith

AU - Barrington, Sally

AU - Radford, John

N1 - Conference code: 10

PY - 2016

Y1 - 2016

KW - Hodgkin lymphoma

KW - Brentuximab vedotin

KW - Antibody drug conjugate

KW - Elderly

KW - Frail

M3 - Conference contribution

BT - . Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity

PB - Ferrata Storti Foundation

T2 - 10th International Symposium for Hodgkin Lymphoma (ISHL)

Y2 - 22 October 2016 through 25 October 2016

ER -

Gibb A, Pirrie S, Linton K, Paterson K, Davies A, Collins GP et al. Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity. In . Results of a phase II study of brentuximab vedotin using a response adapted design for first line treatment of patients with Hodgkin lymphoma who were unsuitable for chemotherapy due to age, frailty or co-morbidity. Ferrata Storti Foundation. 2016